190 related articles for article (PubMed ID: 19204913)
1. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.
Kawasaki BT; Hurt EM; Kalathur M; Duhagon MA; Milner JA; Kim YS; Farrar WL
Prostate; 2009 Jun; 69(8):827-37. PubMed ID: 19204913
[TBL] [Abstract][Full Text] [Related]
2. Thermosensitization and induction of apoptosis or cell-cycle arrest via the MAPK cascade by parthenolide, an NF-κB inhibitor, in human prostate cancer androgen-independent cell lines.
Hayashi S; Koshiba K; Hatashita M; Sato T; Jujo Y; Suzuki R; Tanaka Y; Shioura H
Int J Mol Med; 2011 Dec; 28(6):1033-42. PubMed ID: 21805026
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by parthenolide in human oral cancer cell lines and tumor xenografts.
Yu HJ; Jung JY; Jeong JH; Cho SD; Lee JS
Oral Oncol; 2015 Jun; 51(6):602-9. PubMed ID: 25817195
[TBL] [Abstract][Full Text] [Related]
4. Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway.
Huang L; Liu F; Liu X; Niu L; Sun L; Fang F; Ma K; Hu P
Cancer Chemother Pharmacol; 2024 Mar; 93(3):203-213. PubMed ID: 38141074
[TBL] [Abstract][Full Text] [Related]
5. Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.
Volate SR; Kawasaki BT; Hurt EM; Milner JA; Kim YS; White J; Farrar WL
Mol Cancer Ther; 2010 Feb; 9(2):461-70. PubMed ID: 20124455
[TBL] [Abstract][Full Text] [Related]
6. The sesquiterpene lactone parthenolide inhibits LPS- but not TNF-alpha-induced maturation of human monocyte-derived dendritic cells by inhibition of the p38 mitogen-activated protein kinase pathway.
Uchi H; Arrighi JF; Aubry JP; Furue M; Hauser C
J Allergy Clin Immunol; 2002 Aug; 110(2):269-76. PubMed ID: 12170268
[TBL] [Abstract][Full Text] [Related]
7. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.
Hurt EM; Kawasaki BT; Klarmann GJ; Thomas SB; Farrar WL
Br J Cancer; 2008 Feb; 98(4):756-65. PubMed ID: 18268494
[TBL] [Abstract][Full Text] [Related]
8. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo.
Mendonca MS; Turchan WT; Alpuche ME; Watson CN; Estabrook NC; Chin-Sinex H; Shapiro JB; Imasuen-Williams IE; Rangel G; Gilley DP; Huda N; Crooks PA; Shapiro RH
Free Radic Biol Med; 2017 Nov; 112():318-326. PubMed ID: 28782644
[TBL] [Abstract][Full Text] [Related]
9. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
10. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
Mickova A; Kharaishvili G; Kurfurstova D; Gachechiladze M; Kral M; Vacek O; Pokryvkova B; Mistrik M; Soucek K; Bouchal J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799604
[TBL] [Abstract][Full Text] [Related]
11. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells.
Watson C; Miller DA; Chin-Sinex H; Losch A; Hughes W; Sweeney C; Mendonca MS
Radiat Res; 2009 Apr; 171(4):389-96. PubMed ID: 19397439
[TBL] [Abstract][Full Text] [Related]
12. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.
Morel KL; Ormsby RJ; Solly EL; Tran LNK; Sweeney CJ; Klebe S; Cordes N; Sykes PJ
Clin Exp Metastasis; 2018 Oct; 35(7):649-661. PubMed ID: 29936575
[TBL] [Abstract][Full Text] [Related]
13. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.
Bansal N; Davis S; Tereshchenko I; Budak-Alpdogan T; Zhong H; Stein MN; Kim IY; Dipaola RS; Bertino JR; Sabaawy HE
Prostate; 2014 Feb; 74(2):187-200. PubMed ID: 24154958
[TBL] [Abstract][Full Text] [Related]
14. Thermosensitization by parthenolide in human lung adenocarcinoma A549 cells and p53- and hsp72-independent apoptosis induction via the nuclear factor-kappaB signal pathway.
Hayashi S; Hatashita M; Hayashi A; Matsumoto H; Shioura H; Kitai R
Int J Mol Med; 2008 May; 21(5):585-92. PubMed ID: 18425350
[TBL] [Abstract][Full Text] [Related]
15. Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.
Schlicht M; Matysiak B; Brodzeller T; Wen X; Liu H; Zhou G; Dhir R; Hessner MJ; Tonellato P; Suckow M; Pollard M; Datta MW
BMC Genomics; 2004 Aug; 5(1):58. PubMed ID: 15318950
[TBL] [Abstract][Full Text] [Related]
16. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro.
Steele AJ; Jones DT; Ganeshaguru K; Duke VM; Yogashangary BC; North JM; Lowdell MW; Kottaridis PD; Mehta AB; Prentice AG; Hoffbrand AV; Wickremasinghe RG
Leukemia; 2006 Jun; 20(6):1073-9. PubMed ID: 16628188
[TBL] [Abstract][Full Text] [Related]
17. The plant sesquiterpene lactone parthenolide inhibits Wnt/β-catenin signaling by blocking synthesis of the transcriptional regulators TCF4/LEF1.
Zhu X; Yuan C; Tian C; Li C; Nie F; Song X; Zeng R; Wu D; Hao X; Li L
J Biol Chem; 2018 Apr; 293(14):5335-5344. PubMed ID: 29462785
[TBL] [Abstract][Full Text] [Related]
18. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
Guzman ML; Rossi RM; Karnischky L; Li X; Peterson DR; Howard DS; Jordan CT
Blood; 2005 Jun; 105(11):4163-9. PubMed ID: 15687234
[TBL] [Abstract][Full Text] [Related]
19. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.
An T; Yin H; Lu Y; Liu F
Drug Des Devel Ther; 2022; 16():1255-1272. PubMed ID: 35517982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
